Nesiritide is a recombinant formulation of B-type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 microg.kg(-1).min(-1) were used to control mean arterial pressure while in the other patient, doses of 0.01-0.03 microg.kg(-1).min(-1) were used to augment urine output. The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1460-9592.2004.01398.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extracorporeal Membrane Oxygenation (ECMO) serves as a crucial intervention for patients with severe pulmonary dysfunction by facilitating oxygenation and carbon dioxide removal. While traditional ECMO systems are effective, their large priming volumes and significant blood-contacting surface areas can lead to complications, particularly in neonates and pediatric patients. Microfluidic ECMO systems offer a promising alternative by miniaturizing the ECMO technology, reducing blood volume requirements, and minimizing device surface area to improve safety and efficiency.
View Article and Find Full Text PDFRepairing the mitral valve without touching the mitral valve-a novel technique.
J Surg Case Rep
January 2025
Department of Cardiac Surgery, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AY, United Kingdom.
A 44-year-old gentleman presented with severe ischemic cardiomyopathy and mitral regurgitation post-inferior myocardial infarction. Echocardiography and magnetic resonance imaging revealed a dilated left ventricle with a large left ventricular aneurysm (9.3 × 9.
View Article and Find Full Text PDFA stuck leaflet after balloon post-dilatation in transcatheter aortic valve implantation with a SAPIEN-3 ultra RESILIA valve: a case report.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Komaki City Hospital, 1-20 Joubushi, Komaki, Aichi 485-8520, Japan.
Background: Transcatheter aortic valve implantation (TAVI) is a safe and effective therapy for patients with severe aortic stenosis. A Stuck leaflet and severe intraprosthetic regurgitation after valve implantation occur rarely but can lead to sudden haemodynamic deterioration. We encountered a case of a stuck leaflet following post-dilatation with the Edwards Sapien 3 Ultra RESILIA valve.
View Article and Find Full Text PDFCase report: interventional thrombectomy with haemodynamic support by veno-arterial extracorporeal membrane oxygenation as a rescue strategy in acute pulmonary embolism refractory to systemic thrombolysis.
Eur Heart J Case Rep
January 2025
Department of Cardiology, General Hospital Celle, Siemensplatz 4, Celle 29223, Germany.
Background: High-risk pulmonary embolism (PE) is associated with significant mortality. Thrombolysis is the therapy of choice, while interventional thrombectomy may be a helpful strategy in case of contraindications or failed thrombolysis. However, the procedure may be complicated by catheter-induced embolization of clots and/or haemodynamic compromise.
View Article and Find Full Text PDFExperience with extracorporeal membrane oxygenation support in Latin America between 2016 and 2020.
Med Intensiva (Engl Ed)
January 2025
Servicio ECMO, Fundación Cardiovascular de Colombia, Bucaramanga, Colombia.
Objective: To document the experience with ECMO therapy in healthcare institutions across Latin America between 2016 and 2020.
Design: Cross-sectional study.
Setting: Private and public health institutions from 7 countries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!